Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment

被引:3
|
作者
Wang, Chuanlin [1 ,2 ]
Gao, Pengning [1 ,2 ]
Xu, Jiali [1 ,2 ]
Liu, Shanling [1 ,2 ]
Tian, Wenda [2 ,3 ]
Liu, Jiayu [4 ]
Zhou, Lan [1 ,2 ]
机构
[1] Kunming Med Univ, Yunnan Canc Hosp, Dept Clin Nutr, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[2] Yunnan Canc Ctr, Kunming, Yunnan, Peoples R China
[3] Kunming Med Univ, Yunnan Canc Hosp, Dept Gynecol, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[4] Anhui Med Univ, Key Lab Environm Toxicol Anhui Higher Educ Inst, Sch Publ Hlth, Dept Toxicol, Hefei, Anhui, Peoples R China
关键词
phytochemicals; ovarian cancer; PARP; BRCA; PARP inhibitors; ANTIOXIDANT DEFENSE SYSTEM; ENDOTHELIAL DYSFUNCTION; DNA-REPAIR; DAMAGE; KEAP1; CROCIN; TUMORS; CELLS; NRF2; ROS;
D O I
10.3389/fphar.2022.1078303
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ovarian cancer is among the most common malignant tumors in gynecology and is characterized by insidious onset, poor differentiation, high malignancy, and a high recurrence rate. Numerous studies have shown that poly ADP-ribose polymerase (PARP) inhibitors can improve progression-free survival (PFS) in patients with BRCA-mutated ovarian cancer. With the widespread use of BRCA mutation and PARP inhibitor (PARPi) combination therapy, the side effects associated with BRCA mutation and PARPi have garnered attention worldwide. Mutations in the BRCA gene increase KEAP1-NRF2 ubiquitination and reduce Nrf2 content and cellular antioxidant capacity, which subsequently produces side effects such as cardiovascular endothelial damage and atherosclerosis. PARPi has hematologic toxicity, producing thrombocytopenia, fatigue, nausea, and vomiting. These side effects not only reduce patients' quality of life, but also affect their survival. Studies have shown that natural phytochemicals, a class of compounds with antitumor potential, can effectively prevent and treat the side effects of chemotherapy. Herein, we reviewed the role of natural phytochemicals in disease prevention and treatment in recent years, including sulforaphane, lycopene, catechin, and curcumin, and found that these phytochemicals have significant alleviating effects on atherosclerosis, nausea, and vomiting. Moreover, these mechanisms of action significantly correlated with the side-effect-producing mechanisms of BRCA mutations and PARPi. In conclusion, natural phytochemicals may be effective in alleviating the side effects of BRCA mutant ovarian cancer cells and PARP inhibitors.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
    Angela Cho
    Jeong-Yeol Park
    Shin-Wha Lee
    Dae-Yeon Kim
    Dae-Shik Suh
    Jong-Hyeok Kim
    Yong-Man Kim
    Young-Tak Kim
    Archives of Gynecology and Obstetrics, 2021, 304 : 1055 - 1063
  • [42] Assessing BRCA-mutated ovarian cancer: prognostic factors through combined genetic and epigenetic analysis
    Ergasti, Raffaella
    Marchetti, Claudia
    Piermattei, Alessia
    Valentini, Maria Grazia
    Bonis, Maria De
    Minucci, Angelo
    Nero, Camilla
    Bottoni, Carolina
    Russo, Giorgia
    Camarda, Floriana
    Giaco, Luciano
    Pasciuto, Tina
    Marino, Ilenia
    Fagotti, Anna
    Scambia, Giovanni
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A584 - A585
  • [43] Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
    Kristeleit, Rebecca S.
    Drew, Yvette
    Oza, Amit M.
    Domchek, Susan M.
    Banerjee, Susana
    Glasspool, Rosalind M.
    Balmana, Judith
    Chen, Lee-may
    Patel, Manish R.
    Burris, Howard A.
    Safra, Tamar
    Borrow, Jennifer
    Lin, Kevin K.
    Goble, Sandra
    Maloney, Lara
    Shapira-Frommer, Ronnie
    BRITISH JOURNAL OF CANCER, 2023, 128 (02) : 255 - 265
  • [44] Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
    Rebecca S. Kristeleit
    Yvette Drew
    Amit M. Oza
    Susan M. Domchek
    Susana Banerjee
    Rosalind M. Glasspool
    Judith Balmaña
    Lee-may Chen
    Manish R. Patel
    Howard A. Burris
    Tamar Safra
    Jennifer Borrow
    Kevin K. Lin
    Sandra Goble
    Lara Maloney
    Ronnie Shapira-Frommer
    British Journal of Cancer, 2023, 128 : 255 - 265
  • [45] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
    Cho, Angela
    Park, Jeong-Yeol
    Lee, Shin-Wha
    Kim, Dae-Yeon
    Suh, Dae-Shik
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 304 (04) : 1055 - 1063
  • [46] Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer patients: a single Centre experience
    Maccaroni, E.
    Bracci, R.
    Giampieri, R.
    Bianchi, F.
    Belvederesi, L.
    Brugiati, C.
    Pagliaretta, S.
    Della Mora, A.
    Tronconi, F.
    Pistelli, M.
    Pagliacci, A.
    Battelli, N.
    Ballatore, Z.
    De Lisa, M.
    Berardi, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] PARP Inhibitor Treatment in Ovarian and Breast Cancer
    不详
    CURRENT PROBLEMS IN CANCER, 2011, 35 (01) : 7 - 50
  • [48] Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
    Jain, Aditi
    Barge, Alan
    Parris, Christopher N.
    ONCOGENE, 2025, 44 (04) : 193 - 207
  • [49] Comparisons of survival outcomes between bevacizumab and PARP inhibitors in BRCA-mutated, platinum-sensitive relapsed high-grade serous ovarian cancer
    Kim, Se Ik
    Lee, Maria
    Kim, Hee Seung
    Chung, Hyun Hoon
    Park, Noh Hyun
    Kim, Jae-Weon
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A230 - A230
  • [50] BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PERU
    Torres Toala, F. G.
    Solorzano, J.
    Baldi, J.
    VALUE IN HEALTH, 2018, 21 : S22 - S22